A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Summary

This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.

Timeline

Start

2015-11

Primary completion

2017-02

Completion

2017-02

Drugs

Indications